Arcus Biosciences (RCUS)
(Real Time Quote from BATS)
$9.10 USD
-0.06 (-0.66%)
Updated Aug 4, 2025 01:04 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RCUS 9.10 -0.06(-0.66%)
Will RCUS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RCUS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RCUS
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates
Arcus Biosciences, Inc. (RCUS) Reports Q4 Loss, Tops Revenue Estimates
RCUS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Moderna (MRNA) Stock Jumps 11.7%: Will It Continue to Soar?
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue Estimates
Regeneron (REGN) Tops Q3 Earnings and Revenue Estimates
Other News for RCUS
Arcus Biosciences Inc (RCUS) Announces Equity Awards for New Employee | RCUS stock news
Arcus Biosciences Announces New Employment Inducement Grants | RCUS Stock News
Arcus Biosciences (RCUS) Gains FDA Orphan Drug Status for Pancreatic Cancer Treatment
Arcus says Gilead-partnered cancer drug won FDA orphan status
Arcus Biosciences’ cancer drug gets orphan drug status